Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Silver Bullet Therapeutics, Inc.

http://www.svbtx.com/

Latest From Silver Bullet Therapeutics, Inc.

Silver Bullet Therapeutics Inc.

The standard of care for osteomyelitis has not changed over the past half century: long-term intravenous antibiotics with multiple agents and doses administered daily and typically lasting a full 12 weeks, followed by oral medications for an additional several months to a year. Silver Bullet Therapeutics Inc. is developing a temporary, implantable silver-eluting implant to fight infection in tandem with IV antibiotics. The company's founders say it should shorten the duration of IV therapy by half.

BioPharmaceutical Medical Device

Start-Up Previews (11/2010)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Start-Ups Look For A Place In Coming Hepatitis C Combo Regimens." features profiles of AiCuris, Avila Therapeutics, Okairos, Viroblock and Zirus. Plus these Start-Ups Across Health Care: Arineta, HemoShear, Hygieia and Silver Bullet Therapeutics.

Juvaris BioTherapeutics Inc.

Juvaris BioTherapeutics Inc.'s technology is an offshoot of gene therapy work originally conducted at Valentis. Researchers there discovered that their DNA/lipid delivery combination elicited a mild immune response at the lowest dose. Juvaris has used the technology to develop two classes of products: JuvImmune is made up of the DNA/lipid combination without an antigen and is intended to boost the immune response. Combined with vaccines, where it boosts the intensity of the immune response, the technology is called JuvaVax.

BioPharmaceutical

Genteric Inc.

Genteric is harnessing the body's ductal system to get genes into the gastrointestinal organs and on into the circulation, without directly confronting the circulatory system. The firm believes this direct route will improve transfection rates and reduce immune reactions, regardless of the sort of vector--and has been pitching gene-therapy companies on the concept. So far, they've been hard to convince, but Genteric is confident they will come to appreciate the benefits of its delivery method.

BioPharmaceutical Strategy
See All

Company Information

  • Industry
  • Medical Devices
UsernamePublicRestriction

Register